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Objectives: Network meta-analysis (NMA) is increasingly used to inform reim-
bursement decisions and comparative effectiveness. Nevertheless, there is limited 
understanding of the assessment of statistical power, particularly when there is a 
small number of studies available. We propose an empirical calculation for statistical 
power using a simulation approach. MethOds: Simulation data were generated in 
minimum of 3 to maximum of 15 studies per network, using varying effect sizes and 
standard errors under the exchangeability assumption; where trial-specific treat-
ment effects (δ ij) came from a common distribution with mean (dij ) and variance 
(σ 2). The common distribution is usually chosen to be a normal distribution, so that 
δ ij˜N(dij, σ 2) where i,j are different treatments. Upon generation of simulation data, 
Bayesian methods were applied to each simulation set. This was repeated at least 
1000 times, which enabled the estimation of the statistical power. We compared 
the results of simulations to the gold standard, defined by available data from each 
study, and Thorlund’s method. Results: The proposed method was successful in 
estimating the statistical power and the minimum number of studies needed, using 
simulation data from an NMA, compared to the gold standard. The estimations 
for statistical power/number of studies needed by different effect sizes, standard 
errors, and noise levels were compared with Thorlund’s method showing more 
accuracy to estimate statistical power for NMA. Our method offers flexibility and 
can be implemented with Normal, Binomial, and Poisson distributions. Further, it 
can also handle multiple treatments, fixed/random effects models, and multi-arms 
studies. cOnclusiOns: While it is difficult to derive a mathematical formula for 
estimating statistical power and the number of studies needed in NMA because 
of increased complexity caused by multiple treatment comparisons, an empirical 
method using simulations allows for estimation of these quantities. The proposed 
method will be useful for researchers designing NMA to inform decision makers.
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EconoMics of diabEtEs MEllitus: thEoRy and EvidEncE foR bRazilian 
data in 2008
Balbinotto G.1, Wiest R.1, Jacinto P.2
1Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2puc/rs, PORTO ALEGRE, Brazil
Objectives: to measure the DM social cost based in earnings losses of Brazilian 
workers due to disease in 2008 using data from National Survey of Households 
(PNAD/IBGE). Diabetes Mellitus (DM) is characterized by the high level of blood glu-
cose. Ministry of Health data estimated that Brazil had about 10 million DM cases in 
2010, being the fourth main cause of death. WHO estimated the prevalence of DM in 
Brazil is 10.2%, about 20 million people. MethOds: a Binary Probit model to meas-
ure the participation in work force and a two-stage Heckman model to measure 
worked hours and productivity. Each model is estimated separately for both gender 
individuals, with and without disease, according three distinct definitions for DM: 
Restrict, Broad and Comorbidities. To capture the counterfactual effect, the model 
was calculated for ill and healthy individuals. The difference of both values exhib-
ited the losses, which were aggregate to the whole population and the total cost 
was estimated. Results: According each criterion, respectively, DM reduced the 
participation in the labor market in 0,97%; 4,60% and 7,06% for men and 0,14%; 4,79% 
and 6,44% for women, while reduced, respectively 1,51%; 6,40% and 9,15% in produc-
tivity and 6,44%; 15,23% and 17,58% in worked hours just for women. There was no 
impact of DM on productivity and in worked hours for men. The DM total cost was 
R$ 8,064 billion, or US$ 3,451 billion converted by current exchange rate. The losses 
reached 0,73% of total earnings and 0,27% of Brazilian GDP in 2008. cOnclusiOns: 
DM generates significant losses in income of Brazilian workers, especially in relation 
to their participation in the labor market, since affects both of gender. The results 
indicate that public policies should be directed to disease diagnosis and prevention, 
since the development of comorbidities amplifies the effect of losses.
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Objectives: Cluster analysis (CA) is a widely used statistical technique that helps 
reveal classifications of entities with similar characteristics in large data sets. 
However, little is known about whether it can be applied to healthcare claims data 
with highly skewed cost information. This study applied different clustering meth-
ods to changes in all-cause cost data from a group of patients with end stage renal 
disease (ESRD) who initiated hemodialysis (HD). MethOds: A retrospective, cross-
sectional, observational study was conducted using the MarketScan Commercial 
Claims database. Patients aged ≥18 years with ≥2 ESRD diagnoses who initiated HD 
between 2008 and 2010 were included. The K-means CA method and hierarchical 
CA with various linkage methods were applied to all-cause costs within baseline 
(12-month pre-HD) and follow-up periods (12-month post-HD) to identify clusters. 
Demographic, clinical, and cost information were extracted from both periods, 
and then examined by cluster. Results: A total of 18,380 patients were identified. 
Meaningful all-cause cost clusters were generated using K-means and hierarchical 
CA with either flexible beta or Ward’s methods. Based on cluster sample sizes and 
change of cost patterns, the K-means CA method and 4 clusters were selected: 
those with average costs in both periods (n=16,624); high costs followed by very 
high costs (n=113); high and increasing costs (n=1,554); or very high costs reduced 
to high cost (n=89). Relatively stable costs after starting HD were associated with 
more stable scores on comorbidity index scores from the pre- and post-HD periods, 
while increasing costs were associated with more sharply increasing comorbidity 
by Signorovitch (WS) vs. Entropy Balancing (EB). WS is based on propensity 
score weights (odds of being in AGR trial) while EB relies on a maximum entropy 
reweighting scheme. Results: Simulation show the optimal weighting method 
is to match on covariates against the AGR treatment and control arms separately. 
In addition, rebalancing on prognostic variables between the IPD arms using EB 
is beneficial when they are not reported in AGR. For example, with true treat-
ment mean difference between AGR and IPD (IC) of one, six predictive variables 
in AGR and IPD and three prognostic variables in IPD, the Bucher method gives a 
biased estimate 0.31(Average Bootstrap 95% Confidence interval: -0.45, 1.08). WS 
balancing gives 0.99(0.23 –1.73), balancing on each arm separately gives 0.99(0.30-
1.68) while rebalancing using EB gives 0.99(0.47-1.52). Also, simulations demon-
strate that including placebo response into the weighting in addition to baseline 
covariates can produce biased results and is not recommended. cOnclusiOns: 
MAIC can be improved if weighting is performed on each arm separately 
together with rebalancing of the IPD on the prognostic variables not reported 
in AGR.
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Objectives: In 2012, the FDA issued Drug Safety Communications on several 
drugs associated with QT prolongation and fatal ventricular arrhythmias. Among 
these was citalopram, a selective serotonin reuptake inhibitor (SSRI) commonly 
used to treat posttraumatic stress disorder (PTSD). As minimal research has 
assessed drug-related QT prolongation in patients with severe mental illnesses, 
this study explores psychotropic drugs associated with QT prolongation among 
Veterans diagnosed with PTSD. MethOds: Patients with PTSD in the Veterans 
Health Administration in 2006-2009 were reviewed, identifying 176 Veterans diag-
nosed with QT prolongation. Cases were matched 1:4 on age, gender, visit date and 
setting, and physical comorbidity. Classification trees assessed QT prolongation 
risk among prescribed medications for the combined sample (N= 880). Finally, 
five-year survival by prolonged QT status was analyzed. Results: Receipt of any 
drug with known risk of QT prolongation varied by group (23% QT vs. 15% con-
trol, p< 0.01). Psychotropic medications conferring significant risks included the 
antipsychotic ziprasidone (3% vs. 1%, p= 0.02) and the anxiolytic buspirone (6% 
vs. 2%, p= 0.01) but not the SSRIs citalopram and fluoxetine. Classification trees 
found sotalol and the tricyclic antidepressant amitriptyline carried greater risk 
among cardiac patients, and methadone, especially if prescribed with quetiapine, 
among non-cardiac patients. Per preliminary adjusted survival model, patients 
with QT prolongation were at increased risk for mortality (HR= 1.60; 95% CI: 1.04-
2.44). cOnclusiOns: Decision models are particularly advantageous when 
exploring nonlinear relationships or non-additive interactions. These findings 
may potentially impact clinical decision-making concerning treatment for PTSD. 
For patients at higher risk of QT prolongation, antidepressants other than ami-
triptyline should be considered. Medications for comorbid conditions should also 
be closely monitored for heightened risk of QT prolongation. This study further 
highlights the importance of routine use of electrocardiograms for QT monitoring 
among patients with PTSD taking these agents.
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Objectives: Methods of analyzing real world evidence (RWE) have tradition-
ally focused on population-based outcome assessments, whereas the applica-
tion of RWE to address healthcare decision making for the individual patient 
is less well established. The primary objective of this study was to systemati-
cally review published methods using real world data sources to inform patient-
level and patient-provider decision making. MethOds: A systematic literature 
review was conducted in MEDLINE and PsychInfo from 1/1/2000 to 9/18/2014. The 
search strategy included methodology, design and limited publications to can-
cer, diabetes, cardiovascular, Alzheimer’s disease, and rheumatologic conditions. 
A review of reference lists of identified articles enhanced the search strategy. 
Eligible studies were quantitative research that described statistical method-
ologies applicable to patient-provider decision making. Non-English and non-
human studies were excluded. Articles were also excluded if they were qualitative 
research studies, reviews, policy/guidelines statements, or studies solely inves-
tigating a provider’s perspective. Following dual eligibility review, details of the 
study and research methodology were extracted and summarized. Results: The 
search strategy identified 1088 publications. A preliminary review of 594 articles 
found 46 that were eligible. The methodologies used included prediction models 
based on logistic, multiple regression and Cox-regression models, multivariate 
risk analyses, discrete choice experiments, net reclassification, and classifica-
tion trees. The review is currently ongoing and additional eligible articles will 
be identified. Details of the application of these methods to patient-provider 
decision making will be presented at the meeting. cOnclusiOns: There is a 
need to incorporate methods in research studies to support evidence-based 
patient-level decision making. This systematic literature review has sought to 
identify methods and exemplars that will enable researchers to produce work to 
inform patient-provider decision making. This review will make recommenda-
tions regarding appropriate methods for scientists and investigators conducting 
patient-centered research. Future research should consider these approaches 
to incorporate methods that will support evidence-based patient decision 
making.
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ies, 432 symptom concepts (range 7-33, M= 16.6 [SD] 6.4) were elicited. Each sample 
was divided into quartiles based on the chronology of individual interviews. Study 
results (i.e., patient reports) were then reviewed to determine the interview number 
and quartile in which each concept was first elicited. Results: Analysis showed 
that 84.0% (n= 363), 92.4% (n= 399), 97.2% (n= 420), and 99.3% (n= 429) of all elicited 
concepts had emerged by the tenth, fifteenth, twentieth, and twenty-fifth inter-
view, respectively. Less than 1% (n= 3) of concepts emerged after the 25thinterview 
in samples with > 25 subjects. cOnclusiOns: While a variety of factors inform 
sample size decisions in concept elicitation interview studies, this analysis sug-
gests that researchers can reasonably expect to elicit 95% to 100% of the targeted 
disease-related symptoms-level concepts, and thus achieve saturation, through the 
conduct of 20 to 25 interviews.
PRM133
ExPloRinG thE REal woRld sEttinG of chRonic idioPathic uRticaRia 
and Physician attitudEs towaRds it in thE us
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Objectives: To describe the methodology of a real-world, cross-sectional survey 
of Chronic Idiopathic Urticaria (CIU) in the US, outlining collection of patient-
level data from both physicians and their patients as well as physician attitudi-
nal data. MethOds: The survey, conducted by Adelphi between November 2014 
and March 2015, incorporates Physician Interviews, Patient Record Forms (PRFs) 
completed by physicians, and Patient Self-Completion Forms (PSCs). Physicians 
provide data regarding current clinical practice, CIU history and progression, trig-
gers, continuous/intermittent symptoms, affected body sites, severity and treat-
ment. Patients provide information regarding their disease experience, sleep 
quality (Jenkins questionnaire), effects on daily/working life (Work Productivity 
and Activity Index) and satisfaction with treatment. Physician interviews include 
number of CIU patients managed, tests used to aid diagnosis, circumstances in 
which systemic and biologic therapy are used, and criteria for determining sever-
ity. Eligible physicians (Allergists and Dermatologists) each provided PRFs for 4 
non-refractory and 6 refractory patients. All patients were invited to take part 
anonymously in the self-completion exercise but this was not mandatory. Ethical 
approval was obtained. Results: The target sample is 100 physicians providing 
information on approximately 1000 CIU patients. While patient specific results are 
anticipated to be available from Q2 2015, early physician interview results (n= 5) 
suggest that diagnostic tests performed by up to 80% of specialists include com-
plete blood count, liver tests and anti-thyroglobulin/anti-thyroperoxidase antibody 
tests. The most important factors in determining CIU severity are frequency of 
symptomatic period and impact on quality of life. All of the physicians indicate 
being comfortable prescribing biologics for CIU patients and 4 out of 5 suggest 
they are suitable for 25-33% of their CIU patients. cOnclusiOns: To date limited 
data are available on real world experience of CIU and this cross-sectional survey 
is providing a unique insight into the continuum of care for patients experiencing 
this distressing condition.
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Ho Y.
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Objectives: This study examines comparators used for biologic Rheumatoid 
Arthritis (RA) drugs, both Tumor Necrosis Factor (TNF) drugs and Disease-
Modifying, Anti-Rheumatic Drugs (DMARDs), and the decision compared to the 
European label. The change in comparator categories for RA drugs over time is also 
assessed. MethOds: This research highlights RA Health Technology Assessments 
(HTAs), published from 2005 – 2014, from NICE, SMC, HIS, HAS, and IQWiG. (The 
G-BA did not review RA during this time frame.) Comparators were split into two 
non-mutually-exclusive categories: comparators that included methotrexate, and 
comparators that included DMARDs. Comparators that included methotrexate were 
separated into: methotrexate alone, or methotrexate with other drugs. Comparators 
that included DMARDs were split into: biologics alone, biologics plus methotrexate, 
and conventional DMARDs (no biologics). By matching on indication and time, and 
restricting against the European label, HTA decisions were determined to be either: 
Recommend, Recommend With Restrictions (RWR), Do Not Recommend (DNR), or 
No Decision. Results: The sample included 77 reviews. Twenty-two reviews used 
methotrexate in combination with biologic drugs as comparators. Of these, 13 (59%) 
received a Recommend, six (27%) received RWR, and three (14%) were DNR. The fre-
quency of the use of biologics (alone or in combination) as comparators increased 
each year between 2006, with 14% (1/7), and 2009, with 60% (3/5). In 2009, one (20%) 
of the five reviews was the first to use a biologic exclusively as a comparator, and 
received a decision of Recommend. In 2013, two (13%) of the 15 reviews used biolog-
ics only, and received No Decision. In 2014, all two (100%) of the reviews used bio-
logics alone as comparators, with one receiving a decision of Recommend, and the 
other RWR. cOnclusiOns: While the categories of comparators used in RA varied 
over time, the increased use of biologics in recent years illustrates a steady trend.
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Goolsby Hunter A., Brenneman S.
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Objectives: Survey response rates continue to decline across all modes of admin-
istration for public, private, and government organizations conducting survey 
research. This review examines response rates (RR) for direct-to-patient survey 
studies in health economics and outcomes research (HEOR). MethOds: RR was 
scores. cOnclusiOns: The K-means CA method appeared optimal in healthcare 
claims data with highly skewed cost information when taking into account both 
change of cost patterns and sample size in smallest cluster.
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Objectives: Signorovitch (2010) describes MAIC that focuses on matching one 
study with individual patient data (IPD) to the covariates in one study with aggre-
gated data (AGR). However in most scenarios there are likely to be multiple studies 
with IPD and AGR that need to be included in the Indirect Comparison. In addition 
it may be necessary to extend the network of treatments to include more than the 
two treatments with a single comparator. MethOds: We propose a number of 
potential solutions for including multiple studies and multiple treatments in the 
MAIC and assess these using simulations with the weighting methods proposed by 
Signorovitch(2010) as well as with Entropy Balancing Hainmueller (2012) Results: 
When multiple IPD studies exist then MAIC can be conducted if you consider a)
Pooling IPD studies, into one large study and match against the AGR study or b) 
matching each IPD study against the AGR study. For multiple AGR studies then the 
IPD data can be matched against a) just one AGR study, b) the average patient char-
acteristics from the AGR studies, c) the average mean and variances from the AGR 
studies or d) the distribution of patient characteristics using MCMC from the AGR 
studies. To apply a MAIC in Networks involving multiple studies the choice of study 
to match on could be an issue so it is important that the assumptions surrounding 
the NMA are tested, and only if there is no evidence to suggest inconsistency and 
heterogeneity within the Network, should IPD studies be added to the Network via 
an MAIC. cOnclusiOns: MAIC can be applied in scenarios where you have multi-
ple studies and treatments if the existing Network satisfies the assumptions around 
heterogeneity and inconsistency required when performing Network Meta-Analysis.
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Objectives: We evaluated whether treatment initiation of clopidogrel among 
symptomatic peripheral artery disease (SPAD) was impacted by post-stenting 
prevention of thromboembolic complications in patients with comorbid coro-
nary artery disease (CAD), in spite of primary use as secondary prevention in 
SPAD. MethOds: Patient records from Jan 1, 2006 through June 30, 2010 were 
extracted from the MarketScan Commercial Claims and Encounters database. 
Patients met inclusion criteria if they had a record of SPAD but were excluded if 
they had stroke/TIA or contraindications to anti-platelet therapy. Claims identi-
fied 1 year prior to and 3 years post-earliest record of SPAD were included in the 
analysis. Clopidogrel initiators ± 90 days from the index date were identified. A 
classification tree model was created with the outcome being the likelihood of 
treatment initiation with clopidogrel controlling for select baseline covariates. 
The model used the misclassification criterion, required a minimum of 50 obser-
vations/leaf and a maximum of 2 branches/ node. As a comparison, a stepwise 
logistic regression model was also constructed. Results: Of 16,377 SPAD patients, 
5,164 (32%) initiated clopidogrel treatment. The output model had 18 leaves, rang-
ing from 0.3%-53.4% of the population. The most important variables were PAD 
outpatient payment (importance score (IS) = 1), CAD [IS= 0.89], pre-index percu-
taneous coronary intervention (PCI) [IS= 0.46] and pre-index statin use (IS= 0.33). 
Similar results were obtained with the logistic regression model. The highest prob-
ability leaf for clopidogrel initiation (74.6%; 2.5% of the population) and included 
patients with low PAD outpatient payment (< $145), comorbid CAD, pre-index PCI 
and ≥ 1 pre-index all-cause inpatient admission. cOnclusiOns: Our results show 
clopidogrel use in SPAD patients may be impacted by the presence of comorbid 
CAD and/or prior PCI use. When evaluating the effectiveness of clopidogrel for 
SPAD-related outcomes, comorbid CAD and/or PCI use should be considered as 
confounding variables.
REsEaRch on MEthods – study design
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how Many subjEcts aRE EnouGh foR syMPtoM-focusEd concEPt 
Elicitation studiEs? a REtRosPEctivE analysis of satuRation acRoss 
twEnty-six studiEs
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Objectives: As an indicator that concept elicitation study results are robust and 
trustworthy, the value of demonstrating saturation (i.e., the point at which no new 
information is gained from conducting additional interviews) in qualitative research 
is widely accepted. Nevertheless, there is little empirical evidence to guide research-
ers in making a prioridecisions regarding sample size in such studies. This study 
sought to assist in providing such evidence. MethOds: A retrospective analysis of 
saturation results from n= 26 concept elicitation studies completed between 2006 
and 2013 was conducted. Studies included a total of n= 633 subjects (57% female), 
representing a spectrum of therapeutic categories, ages (M= 47.5 [SD] 17.2 years), eth-
nicities (33% non-Caucasian), and education status (25.8% with high school degree 
or less). The vast majority of the interviews were conducted in the US (99.2%) across 
25 states. Study sample sizes ranged from 10-43 (M= 20.9 [SD] 8.1). Across all stud-
